Welcome to our dedicated page for Revolution SEC filings (Ticker: RVMDW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Revolution's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Revolution's regulatory disclosures and financial reporting.
Revolution Medicines General Counsel Jeff Cislini reported selling 2,958 shares of common stock in two open-market transactions. On March 17, he sold 1,795 shares at $99.4804 per share, and on March 19 he sold 1,163 shares at $97.44 per share. One sale was made under a Rule 10b5-1 instruction letter related to tax withholding on vested RSUs, and the other under a 10b5-1 trading plan. After these sales, he directly holds 58,518 shares, including 48,125 RSUs.
Revolution Medicines General Counsel Jeff Cislini reported selling 2,958 shares of common stock in two open-market transactions. On March 17, he sold 1,795 shares at $99.4804 per share, and on March 19 he sold 1,163 shares at $97.44 per share. One sale was made under a Rule 10b5-1 instruction letter related to tax withholding on vested RSUs, and the other under a 10b5-1 trading plan. After these sales, he directly holds 58,518 shares, including 48,125 RSUs.
Revolution Medicines, Inc. officer Wang Xiaolin reported an open-market sale of 2,010 shares of common stock on March 17, 2026 at an average price of $99.4804 per share. The transaction was executed under a pre-arranged Rule 10b5-1 instruction letter to cover tax withholding on vested RSUs. Following the sale, Wang holds 116,063 shares directly, including 48,700 restricted stock units.
Revolution Medicines, Inc. officer Wang Xiaolin reported an open-market sale of 2,010 shares of common stock on March 17, 2026 at an average price of $99.4804 per share. The transaction was executed under a pre-arranged Rule 10b5-1 instruction letter to cover tax withholding on vested RSUs. Following the sale, Wang holds 116,063 shares directly, including 48,700 restricted stock units.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to proposed sales of restricted stock units tied to RVMD stock. The filing lists a sale method and shows prior sales by Jeffrey Todd Cislini of 2,053 shares on 03/16/2026 and 908 shares on 01/21/2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to proposed sales of restricted stock units tied to RVMD stock. The filing lists a sale method and shows prior sales by Jeffrey Todd Cislini of 2,053 shares on 03/16/2026 and 908 shares on 01/21/2026.
Revolution Medicines, Inc. director Elizabeth M. Anderson reported two bona fide gifts of common stock totaling 30,000 shares. The gifts, coded as "G" transactions, occurred on March 4, 2026 at a reported price of $0.00 per share, indicating non-cash charitable or personal transfers.
After these transactions, Anderson holds 8,215 shares directly and 26,990 shares indirectly. The indirect holdings include 3,142 restricted stock units and shares held by trusts, including the Irrevocable Deed of Trust of David W. Anderson and Elizabeth M. Anderson and the David W. Anderson 1996 Irrevocable Trust.
Revolution Medicines, Inc. director Elizabeth M. Anderson reported two bona fide gifts of common stock totaling 30,000 shares. The gifts, coded as "G" transactions, occurred on March 4, 2026 at a reported price of $0.00 per share, indicating non-cash charitable or personal transfers.
After these transactions, Anderson holds 8,215 shares directly and 26,990 shares indirectly. The indirect holdings include 3,142 restricted stock units and shares held by trusts, including the Irrevocable Deed of Trust of David W. Anderson and Elizabeth M. Anderson and the David W. Anderson 1996 Irrevocable Trust.
Revolution Medicines, Inc. reported that officer Xiaolin Wang received equity awards on March 1, 2026. Wang was granted stock options for 34,000 shares at an exercise price of $0.00 and 15,100 shares of common stock, both as awards rather than open-market purchases.
Following the common stock grant, Wang directly owned 118,073 common shares, which includes 54,464 restricted stock units and 652 shares acquired under the employee stock purchase plan. The option award vests in equal monthly installments over four years starting March 1, 2026, contingent on continued service.
Revolution Medicines, Inc. reported that officer Xiaolin Wang received equity awards on March 1, 2026. Wang was granted stock options for 34,000 shares at an exercise price of $0.00 and 15,100 shares of common stock, both as awards rather than open-market purchases.
Following the common stock grant, Wang directly owned 118,073 common shares, which includes 54,464 restricted stock units and 652 shares acquired under the employee stock purchase plan. The option award vests in equal monthly installments over four years starting March 1, 2026, contingent on continued service.
Revolution Medicines, Inc. officer Stephen Michael Kelsey reported equity awards that increased his direct holdings. He received a stock option covering 47,600 shares of common stock at an exercise price of $0.00 per share, characterized as a grant or award acquisition. He also acquired 21,100 shares of common stock as a separate grant, bringing his directly held common shares to 299,700, which includes 94,676 restricted stock units. The option vests in equal monthly installments over four years starting March 1, 2026, with one forty-eighth of the shares vesting each month so that all option shares are fully vested on the fourth anniversary, contingent on his continued service.
Revolution Medicines, Inc. officer Stephen Michael Kelsey reported equity awards that increased his direct holdings. He received a stock option covering 47,600 shares of common stock at an exercise price of $0.00 per share, characterized as a grant or award acquisition. He also acquired 21,100 shares of common stock as a separate grant, bringing his directly held common shares to 299,700, which includes 94,676 restricted stock units. The option vests in equal monthly installments over four years starting March 1, 2026, with one forty-eighth of the shares vesting each month so that all option shares are fully vested on the fourth anniversary, contingent on his continued service.
Revolution Medicines director and officer Mark A. Goldsmith reported option grants, share awards, option exercises and planned sales in RVMD stock. On March 1, 2026, he received stock options for 128,600 shares and 57,100 shares of common stock as grants, with the options vesting monthly over four years starting March 1, 2026.
On March 2, 2026, he exercised 30,000 stock options and acquired 30,000 common shares, then related accounts sold a total of 36,000 common shares in multiple open‑market trades around $98–$102 per share, including sales by family trusts under a Rule 10b5‑1 trading plan. After these transactions, he held 318,869 common shares directly plus additional shares indirectly through trusts, including 225,863 restricted stock units.
Revolution Medicines director and officer Mark A. Goldsmith reported option grants, share awards, option exercises and planned sales in RVMD stock. On March 1, 2026, he received stock options for 128,600 shares and 57,100 shares of common stock as grants, with the options vesting monthly over four years starting March 1, 2026.
On March 2, 2026, he exercised 30,000 stock options and acquired 30,000 common shares, then related accounts sold a total of 36,000 common shares in multiple open‑market trades around $98–$102 per share, including sales by family trusts under a Rule 10b5‑1 trading plan. After these transactions, he held 318,869 common shares directly plus additional shares indirectly through trusts, including 225,863 restricted stock units.
Horn Margaret A reported acquisition or exercise transactions in this Form 4 filing.
Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn reported equity awards consisting of a stock option for 47,600 shares and a grant of 21,100 shares of common stock. The option vests in equal monthly installments over four years starting March 1, 2026, contingent on her continued service.
Horn Margaret A reported acquisition or exercise transactions in this Form 4 filing.
Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn reported equity awards consisting of a stock option for 47,600 shares and a grant of 21,100 shares of common stock. The option vests in equal monthly installments over four years starting March 1, 2026, contingent on her continued service.
Revolution Medicines, Inc. reported that General Counsel Jeff Cislini received equity awards. He was granted a stock option for 32,500 shares at an exercise price of $0.00 and an award of 14,500 shares of common stock. The option vests in equal monthly installments over four years starting on March 1, 2026, becoming fully vested on the fourth anniversary, subject to his continued service.
Revolution Medicines, Inc. reported that General Counsel Jeff Cislini received equity awards. He was granted a stock option for 32,500 shares at an exercise price of $0.00 and an award of 14,500 shares of common stock. The option vests in equal monthly installments over four years starting on March 1, 2026, becoming fully vested on the fourth anniversary, subject to his continued service.
Revolution Medicines, Inc. reported that Chief Financial Officer Anders Jack acquired new equity awards. On March 1, 2026, he received a stock option covering 45,400 shares at an exercise price of $0.00 per share and a grant of 20,200 shares of common stock, both recorded as direct ownership.
The filing states that shares held include 62,538 restricted stock units. The option vests in equal monthly installments over 48 months starting March 1, 2026, so that all 45,400 option shares are fully vested and exercisable by the fourth anniversary, contingent on his continued service.
Revolution Medicines, Inc. reported that Chief Financial Officer Anders Jack acquired new equity awards. On March 1, 2026, he received a stock option covering 45,400 shares at an exercise price of $0.00 per share and a grant of 20,200 shares of common stock, both recorded as direct ownership.
The filing states that shares held include 62,538 restricted stock units. The option vests in equal monthly installments over 48 months starting March 1, 2026, so that all 45,400 option shares are fully vested and exercisable by the fourth anniversary, contingent on his continued service.